HOME >> BIOLOGY >> NEWS
Studies At Cedars-Sinai Confirm Identity Of An Elusive 'Receptor' In Human Cells -- A Breakthrough In Understanding, Fighting Septic Shock

For years, doctors and scientists have sought to understand a complicated mechanism that triggers an over-aggressive immune response in many patients who suffer from severe microbial infections. This immune system overreaction often leads to septic shock, for which no reliable treatments have been found.

Recent data from the Centers for Disease Control and Prevention in Atlanta show that mortality from infectious diseases in the United States has been increasing in recent years, and the number of deaths due to septicemia almost doubled from 4.2 to 7.7 per 100,000, between 1980 and 1992. Infectious diseases now rank third among leading causes of death in the United States, following only cardiovascular diseases and cancer. Furthermore, recent research has linked even cardiovascular diseases and some cancers to infectious diseases.

In a study headed by researchers at Cedars-Sinai Medical Center, scientists have for the first time identified in actual human cells a "receptor" that may be a key component of the process that leads to septic shock, confirming suspicions raised in other recently published studies. In fact, the existence of these receptors -- called Toll-like receptors -- has been the subject of a recent flurry of research.

Data showing this latest evidence was accepted for rapid publication in the March 19 issue of the Journal of Biological Chemistry. Doctors hope this breakthrough may lead to new and more effective approaches for the treatment of severe bacterial infections and endotoxin-associated septic shock that claim thousands of lives each year.

When bacteria from an infection at any site in the body invade the bloodstream, a condition known as septicemia, patients typically experience a variety of symptoms, including chills and fever, and the bacteria are able to travel throughout the body. In 40 to 70 percent of these cases, septic shock follows, characterized by a drop in the blood pressure, multiple organ failure, circulatory
'"/>

Contact: Sandra Van
Sandy@VanCommunications.com
1-800-396-1002
Cedars-Sinai Medical Center
30-Mar-1999


Page: 1 2 3 4 5 6

Related biology news :

1. Monkey business: Studies show tiny callimicos have unusual characteristics
2. Studies show success of Mectizan partnerships
3. Studies offer new insight into HIV vaccine development
4. Studies suggest brain injury results from developmental exposure to alcohol, anesthesia, and lead
5. Studies show preventive value of food supplements
6. Studies probe rapid evolution of Chinese tallow trees
7. Studies of rare blood syndrome yield novel route to cancer
8. Studies dispute ultraviolet effect on amphibian population declines
9. Studies of spiders silk reveal unusual strength
10. Studies of genes in mice and common worm may accelerate research on blood diseases, cancers
11. Studies offer data on potential impact of Reminyl on caregiver burden in Alzheimers disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... 20, 2020 , ... NDA Partners Chairman Carl Peck, ... with expertise in clinical trial planning and feasibility, regulatory inspection readiness, and clinical ... his career, Mr. Movahhed has helped design and manage oncology, neurology, cardiovascular, and ...
(Date:8/7/2020)... ... August 06, 2020 , ... Nine ... prestigious National STEM Scholar Program, a unique professional development program that provides advanced ... for middle school science teachers nationwide. , Created in partnership between the National ...
(Date:7/31/2020)... FRANCISCO (PRWEB) , ... July 30, 2020 , ... ... maturing prescription digital therapeutics product portfolio with a near term focus on Type ... biotech and pharma commercialization experience across multiple therapeutic areas and classes. As Chief ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... ... firm, is making available for free its new white paper – Simulated ... simulation testing into today’s biologics licensing application (BLA). In response, Modality Solutions ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly ... closed on the purchase of greenfield for a new, expanded manufacturing facility. The ... 21 acres in the initial acquisition, with an option to purchase an additional ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands ... , Known as MediVet Biologics since its formation in 2016, the company is ... Animal Health will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... today announced the launch of its new tagline, “BUILDING FOR LIFE.” The adoption ... industry and around the globe, requiring fast track capacity to provide patients with ...
Breaking Biology Technology:
Cached News: